PRODUCT DESCRIPTION:

Somatropin is a recombinant human growth hormone (rhGH) identical to natural growth hormone produced by the pituitary gland. It plays a crucial role in growth, metabolism, and cellular regeneration. This injectable formulation is used for a wide range of growth hormone deficiencies and related disorders in both pediatric and adult populations.

Our product is developed through advanced recombinant DNA technology, ensuring high purity, bioactivity, and international compliance. It is manufactured in GMP-certified and regulatory-audited facilities, suitable for global distribution under hospital supply, specialty endocrine programs, and biosimilar markets.

Formulation & Presentation:

• Dosage Form: Injections
• Presentation: Vial or pre-filled ampoules (customizable as per market demand)
• Available Strengths: 4 IU, 10 IU, 12 IU, 16 IU, 24 IU
• Route of Administration: Sub-Cutaneous (As per physician’s discretion or therapeutic indication)

Therapeutic Indications:

• Growth Hormone Deficiency (GHD) in children and adults
• Turner Syndrome
• Chronic Renal Insufficiency–related growth failure
• Short stature associated with Noonan Syndrome or Prader-Willi Syndrome
• HIV/AIDS-related muscle wasting
• Small for Gestational Age (SGA) with no catch-up growth
• Adjunct in ART (investigational)
• Off-label uses under physician guidance: Anti-aging, muscle mass enhancement (regulated use only)

Side Effects:

• COMMON:  Injection site pain or redness, Edema (fluid retention), Joint pain (arthralgia), Muscle pain, Headache
• SERIOUS (RARE): Intracranial hypertension, Slipped capital femoral epiphysis in pediatric use, Hyperglycemia or insulin resistance, Hypothyroidism, Allergic reactions or anaphylaxis
• PRECAUTIONS: 
  • Use only under supervision of an endocrinologist or qualified healthcare provider
  • Contraindicated in patients with active malignancy
  • Monitor blood glucose and thyroid function regularly
  • Rotate injection sites to avoid lipodystrophy
  • Do not use if hypersensitive to somatropin or any excipients
  • Not for use in patients with acute critical illness (e.g., post-surgical complications)